News & Events

7.2017

Dr. Amit Michaeli, Pepticom's CTO, is invited speaker at the BASEL LIFE Peptide Therapeutic Forum on September 12-13 2017. For more information: amit.michaeli@pepticom.com

7.2017

Pepticom's CEO attended and presented the company and the technology in the Shenzhen International Bio-Valley event.

7.2017

Pepticom will attend the PEPTIDES conference in London, on July 6-7. For more information:maayan.elias@pepticom.com

6.2017

Pepticom's CTO, Amit Michaeli, will give a talk about Artificial intelligence designed TLR4 peptide activators" on September 12 at the Peptide Therapeutics Forum 2017 (part of Basel life 2017). "

6.2017

Pepticom congratulates Prof. Amiram Goldblum, founder and director, for winning the prestigious 2017 Kaye Innovation awards for dramatic improvements in drug discovery methods.

6.2017

Pepticom will attend the 3rd INNOVATION China-Israel investment summit in China. For more information and schedule: andre.miodezky@pepticom.com

6.2017

Pepticom's CEO, Dr.immanuel lerner will attend the 2017 BIO International Convention, June 19-22 in San Diego, California. For more information:maayan.elias@pepticom.com

6.2017

Pepticom is honored to join the Israeli delegation to SelectUSA 2017, bringing our unique technology together with American minds to create leading products in the 21st century. Come and meet us: amit.michaeli@pepticom.com

5.2017

Pepticom was selected as one of the 500 most promising tech startups to participate in the Pioneers Festival 2017 at the Hofburg Imperial Palace in Vienna. Come and meet us on June 1st &2nd. For more information please contact: maayan.elias@pepticom.com

4.2017

Meet us at the Israeli BioMed 2017! May 25th at booth 8 in the startup pavilion area. For more info contact: maayan.elias@pepticom.com

3.2017

Pepticom and Hadasit Medical Research and Services Ltd., the technology transfer company of Hadassah University Hospitals, on behalf of Prof. Dina Ben Yehuda, Head of the department of Hematology, signed a collaboration agreement for the development of novel anti-cancer molecules

1.2017

The EUREKA project, DENOSYNTRAC, performed with Fraunhofer institute and EMC microcollection in Germany, was successfully completed with the discovery of a large library of Immuno-active peptides

11.2016

Invited speaker to the Connex-Yissum event in Jerusalem

11.2016

Pepticom attended the 2016 EuroPEPTIDE conference (part of TIDES) in Berlin, Germany

11.2016

Pepticom increases technology capacity to small-molecule discovery

9.2016

Pepticom attended the 2016 BioSpain conference in Bilbao, Spain as part of the official Israeli delegation

06.2016

Pepticom would like to thank US president Barack Obama, Secretary of State John Kerry, Ambassador Shapiro and the great staff at the US Embassy for an excellent SelectUSA2016 summit!

2.2016

BIOCEV director prof. Paul Mart?sek visits Pepticom to discuss future collaborations

11.2015

Invited speakers at JBNF pitch event

8.2015

Pepticom's technology was successfully implemented in the discovery of a stabilizing peptide for glycogen branching enzyme (GBE) in collaboration with Oxford university and Hadassah medical center. See article "Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design" (human molecular genetics July 2015)

6.2015

Invited speakers at VLX summer event "Rebuilding Traditional Business Models in Healthcare".

5.2015

Pepticom has entered into a collaboration with ADAMA Agricultural Solutions Ltd. (formerly Makhteshim Agan Industries Ltd.).

3.2015

Invited speakers at the best of both event in Leipzig

12.2014

Pepticom initiated research geared at small molecule discovery, based on the exclusive pharmacophore of its binding peptides.

9.2014

Dozens of new peptide modulators discovered and validated in innate immunity, Alzheimerís and cancer projects.

5.2014

Invited speakers in BioMed Israel innovation conference.

3.2014

Pepticom announces a collaboration with Professor Alan S. Kopin at Tufts Medical Center in Boston to develop opioid receptor modulators.

2.2014

Pepticom announces collaboration with Fraunhofer institute to develop innate immunity modulators.

1.2014

EUREKA label approved for Pepticom in joint collaboration with EMC Microcollections and Stuttgart University (IGVP, Stuttgart), to develop Toll-like receptors modulators.

12.2013

EUREKA label approved for pepticom and TargetEx on development of new anti-Alzheimerís disease drugs by designing BACE1 and AChE binding peptides.

12.2013

New pending patent issued by pepticom in the field of innate immunity.

10.2013

Pepticom offices move to a new location: Malha Technology Park (GATI), Building 8, 3rd floor, Jerusalem, Israel.

9.2013

Pepticom initiates multiple projects in the fields of neurology, cancer and cardiovascular diseases.

8.2013

Pepticom undergoes seed investment.